Insight

Stephen V Liu Shared ORCHARD Study Results on Osimertinib Plus Necitumumab in EGFR-Mutated NSCLC Published in JCO

Stephen V Liu/X

Jun 8, 2025, 16:34

Stephen V Liu Shared ORCHARD Study Results on Osimertinib Plus Necitumumab in EGFR-Mutated NSCLC Published in JCO

Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:

“Results from Osimertinib + Necitumumab module of phase II ORCHARD study published in JCO.

Patients with EGFR-Mutated NSCLC with progression on osi and EGFR amplification or secondary EGFR mt received Osimertinib 80mg + Necitumumab D1/8 q21d. RR 11%, PFS 4m, OS 11.4m, 53% had G3+ AE.”

Title: ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib

Journal: JCO

Authors: Jonathan W. Riess, Adrianus J. de Langen, Santiago Ponce, Sarah B. Goldberg, Zofia Piotrowska, Jonathan W. Goldman, Xiuning Le, Byoung Chul Cho, Yasuto Yoneshima, Helen Ambrose, Riccardo Cavazzina, Kwan Ho Tang, James Lau, Helena A. Yu

Read the full article.

ORCHARD

Adrianus J de Langen Byoung Chul Cho cancer EGFR-mutated NSCLC Georgetown University Helen Ambrose Helena A. Yu James Lau Jonathan W. Goldman Jonathan W. Riess Kwan Ho Tang Necitumumab OncoDaily Oncology ORCHARD osimertinib Riccardo Cavazzina Santiago Ponce Sarah B. Goldberg Stephen V Liu Xiuning Le Yasuto Yoneshima Zofia Piotrowska

Garo Armen Shares a Personal Story Driving Agenus' Mission in Cancer Care

Dr. Oliver Bogler, PhD: Leaving the National Cancer Institute

Oncologist Near Me – Rana McKay: A Rising Force in Genitourinary Cancer Research and Care

Sibylle Loibl: Final survival Results from the PENELOPE-B trial published in Annals of Oncology

Yvonne Awards 2025: Honoring Global Oncology Leaders at ASCO’s Most Inspiring Night